This is therefore a comparing of the analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership in Affimed N.V. (NASDAQ:AFMD) and TG Therapeutics Inc. (NASDAQ:TGTX). The two are both Biotechnology companies that compete with one another.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Affimed N.V.	N/A	0.00	N/A	-0.70	0.00
TG Therapeutics Inc.	N/A	4562.37	173.48M	-2.08	0.00

Table 1 demonstrates Affimed N.V. and TG Therapeutics Inc.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 represents Affimed N.V. (NASDAQ:AFMD) and TG Therapeutics Inc. (NASDAQ:TGTX)’s return on assets, return on equity and net margins.

	Net Margins	Return on Equity	Return on Assets
Affimed N.V.	0.00%	-82.1%	-63.5%
TG Therapeutics Inc.	0.00%	-185%	-127.1%

Risk & Volatility

Affimed N.V.’s 3.34 beta indicates that its volatility is 234.00% more volatile than that of S&P 500. Competitively, TG Therapeutics Inc. is 114.00% more volatile than S&P 500, because of the 2.14 beta.

Liquidity

The Current Ratio and Quick Ratio of Affimed N.V. are 3.7 and 3.6 respectively. Its competitor TG Therapeutics Inc.’s Current Ratio is 2.7 and its Quick Ratio is 2.7. Affimed N.V. can pay off short and long-term obligations better than TG Therapeutics Inc.

Analyst Recommendations

The table given features the ratings and recommendations for Affimed N.V. and TG Therapeutics Inc.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Affimed N.V.	0	0	1	3.00
TG Therapeutics Inc.	0	0	2	3.00

$8 is Affimed N.V.’s average target price while its potential upside is 97.53%. Competitively the average target price of TG Therapeutics Inc. is $17.5, which is potential 106.61% upside. Based on the data given earlier, TG Therapeutics Inc. is looking more favorable than Affimed N.V., analysts view.

Institutional and Insider Ownership

Affimed N.V. and TG Therapeutics Inc. has shares held by institutional investors as follows: 41.9% and 66.1%. Insiders held roughly 12.63% of Affimed N.V.’s shares. Insiders Competitively, held 0.5% of TG Therapeutics Inc. shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Affimed N.V.	5.8%	6.41%	-18.34%	-40.65%	56.99%	17.36%
TG Therapeutics Inc.	37.7%	66.59%	34.45%	-45.58%	-52.57%	66.59%

For the past year Affimed N.V. was less bullish than TG Therapeutics Inc.

Summary

Affimed N.V. beats TG Therapeutics Inc. on 5 of the 8 factors.

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in Germany and internationally. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb designed for the treatment of CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma. The companyÂ’s product candidates include AFM24, a NK-cell that treats epidermal growth factor receptor expressing solid tumors, such as lung, head, neck, and colon cancers; AFM26, which binds to B-cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma. Its product candidates also comprise AFM11, a T-cell TandAb, which is in Phase I clinical trial for the treatment of various CD19+ B-cell malignancies, including non-Hodgkin Lymphoma and acute lymphocytic leukemia; and AMV564, a CD33/CD3-specific T-cell TandAb for the treatment of acute myeloid leukemia and other hematologic malignancies. The company has license agreements with Amphivena Therapeutics, Inc., Deutsches Krebsforschungszentrum, and Xoma Ireland Limited; research funding agreement with The Leukemia & Lymphoma Society; and collaboration with Merck Sharp & Dohme B.V. It also has a clinical development and commercialization collaboration with The University of Texas MD Anderson Cancer Center to evaluate AFM13 in combination with MD AndersonÂ’s NK-cell product. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory non-HodgkinÂ’s lymphoma and chronic lymphocytic leukemia. The company also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies. In addition, it develops a pre-clinical program to develop interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors; bromodomain and extra terminal (BET) inhibitor program in the field of hematological malignancies; and anti-PD-L1 and anti-GITR antibody research programs that are in pre-clinical development stage in the field of hematological malignancies. The company has license agreements with LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, and Ildong Pharmaceutical Co. Ltd. for the development and commercialization of TG-1101 (ublituximab); Rhizen Pharmaceuticals, SA for the development and commercialization of TGR-1202; Ligand Pharmaceuticals Incorporated for the development and commercialization of IRAK4 inhibitor technology; Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs; and Jubilant Biosys for the development and commercialization of BET inhibitor program. TG Therapeutics, Inc. is headquartered in New York, New York.